| HOME >> BIOLOGY >> TECHNOLOGY |
BERKELEY, Calif., Sept. 21 /PRNewswire/ -- Nile Therapeutics Inc., (OTC Bulletin Board: SPDU) a biopharmaceutical company focusing on developing therapies for cardiovascular disease, is pleased to announce the appointments of Daron Evans as its Chief Financial Officer and Jennifer Hodge as the Vice President of Development.
Mr. Evans joined Nile in February 2007 as our Chief Operating Officer, and was appointed Chief Financial Officer in August 2007. In his new role, Mr. Evans will be responsible for overseeing our accounting and finance operations, as well as our compliance with Securities and Exchange Commission reporting obligations. At the same time, Mr. Evans will contribute his substantial operational, business development and entrepreneurial experience in executing our business strategy. Prior to joining Nile, from 2006 to 2007, Mr. Evans served as Director of Business Assessment at Vistakon, a Johnson & Johnson company. Prior to that, from 2004 to 2006, he was a Director of Portfolio & Business Analytics for Scios R&D, a Johnson & Johnson company. Mr. Evans was also a co-founder of a biotechnology diagnostic company, and has worked as a management consultant in the pharmaceutical industry with Booz Allen Hamilton. Mr. Evans received his Masters in Business Administration degree from The Fuqua School of Business at the Duke University, his Master of Science in Biomedical Engineering from Southwestern Medical School & University of Texas at Arlington and his Bachelor of Science in Chemical Engineering from Rice University.
Ms. Hodge joined Nile in August 2007 as the Vice President of
Development. Prior to joining Nile, since 2000 Ms. Hodge worked at CV
Therapeutics, Inc., ("CVT"), where she most recently served as the Director
of Project Management. Prior to CVT, Ms. Hodge was a Global Clinical Team
Leader at Quintiles and held Clinical Research Associate positions at
Otsuka and Solvay. Ms. Hodge also held pharmacologist and development
mana
'/>"/>
| SOURCE Nile Therapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved |